Eurican L multi
Active substance
ATC code
Species
Dogs
Indications
Active immunisation of dogs to:
- prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae
- prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola.
- prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
- prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.**
Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains.
Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains.
* For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity.
** For Leptospira Copenhageni the duration of immunity was not established.
Dose to be administered and administration route
When Eurican Lmulti is used alone, inject a 1-ml dose subcutaneously
When Eurican Lmulti is used as a diluent of a Boehringer Ingelheim freeze-dried vaccine against distemper, adenovirosis, parvovirosis and parainfluenza type 2, aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose.
The following schedule should be followed:
Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age.
Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis.
Adverse reactions
A slight swelling (≤ 2 cm) at the injection site may commonly be observed after injection. It usually regresses within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also commonly be observed.
Anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may uncommonly be observed.
Hypersensitivity reactions (facial oedema, anaphylactic shock, urticaria) may rarely occur, some of which are life-threatening. Appropriate symptomatic treatment should promptly be provided.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 08327/4264 |
| EAN | 3661103049838 |
